MEDICAL

en
12 Members

Cards

Recommended

Significant Impact of COVID-19 on Spinal Imaging in Healthcare Industry
COVID-19 Impact on Spinal Imaging in Healthcare Industry The rapid spread of COVID-19 around the world with over 16.3 million cases and over 6,49,000 deaths brings new challenges for the all the communities around the word. The Coronavirus disease (COVID-19) pandemic outbreak has affected, inflicted and influenced million human life’s across all regions ranging from North America, Europe, Asia-Pacific, Middle East and Africa up to South America. The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus has spread across all regions ranging from Asia-Pacific, Europe, North America, Middle East and Africa and South America. World Health Organization (WHO) has been declared Coronavirus disease (COVID-19) pandemic outbreak as a public health emergency of international concern (PHEIC) due to its rapid spread and contagious nature which is a life threating disease. The pandemic outbreak has impacted all the countries either in larger or smaller way and forced national and international authorities and governments to taken unprecedented actions to limit Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus spread. The Coronavirus disease (COVID-19) pandemic outbreak has enforced governments, national and international authorities to impose imposed isolation & lockdowns, close borders, businesses in the order to safeguard lives and wide-spread closures in limit and slowdown the wide-spread of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Countries are facing a many layers emergency which is composed of international and domestic economic disruptions in demand and supply, collapse of prices and straining health systems. Various authorities have made certain efforts and taking actions in the order to give pace to spending behavioural. The Coronavirus disease (COVID-19) pandemic outbreak crisis has affected global economy and created economic recessions in serval countries around the world. As per the International Monetary Fund “The global economy is projected to contract sharply by 3% in 2020, much worse than during the 2008–09 financial crises. The global economy is projected to grow by 5.8% in 2021 as economic activity normalizes. Global growth: for 2020 it is negative—a recession at least as bad as during the global financial crisis or worse.” According to the United Nations “The global economy could shrink by up to 1% in 2020 due to the Coronavirus pandemic, a reversal from the previous forecast of 2.5% growth rate” and “Millions of workers in these countries are facing the bleak prospect of losing their jobs. Governments are considering and rolling out large stimulus packages to avert a sharp downturn of their economies which could potentially plunge the global economy into a deep recession. In the worst-case scenario, the world economy could contract by 0.9% in 2020". The Coronavirus disease (COVID-19) pandemic outbreak by unprecedented strain by spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus has entirely changed Spinal Imaging market dynamics worldwide. Spinal Imaging practices have been drastically impacted irrespective of specialties as all healthcare providers are trying to triage the only urgency of daily imaging procedures and to find new ways and methods for management of less urgent imaging procedure where possible, which has drastically changed in the demand of Spinal Imaging devices and equipment. Moreover, Coronavirus disease (COVID-19) pandemic outbreak arisen uncertainties have concerning the global market. Measures taken to limit and slow the transmission rate of Coronavirus disease (COVID-19) are decreasing the spinal imaging demand. Hospital emergency preparations in the order to expand capacity for the crisis are further diminishing the demand and volume of spinal imaging which can be performed safely. History tells us that Economic recessions majorly tend to result in declined healthcare expenditures and spending. Healthcare groups have never faced any shock which is simultaneously exacerbated though the strict requirements of restrict the availability of imaging. Outpatient procedures are facing the biggest impact of these challenges. However, all spinal - imaging volumes will decrease. Anecdotal experience depicts that spinal imaging practices will anticipate 50%-70% decrease in imaging volume which can last at least of 3-4 months which will depend on the geographic location and practices and the severity of the COVID-19 pandemic in each region. Various reports has presented that imaging industry delinked volume and demand of device around the world and data collected from various countries depicts that only majority of the imaging procedures are categorized as non-essential imaging procedures which have been cancelled during the peak period of the COVID-19 which has affected the spinal imaging market and equipment revenue has been declined in the duration. Spinal imaging equipment manufacturers are currently operating under contingency plans and risk management, workforce safety protocols, manufacturing operations, all at the same time. Some Spinal Imaging equipment manufacturing have established emergency response task force in the order to resolve any challenges as soon as possible to keep the business as operative as maximum as possible and to have understanding of all the situations and scenarios of their challenges and issue associated with the supply & demand in the market. Various autonomous authorities, Regulatory authorities and governments including World Health Organisation, European Medicines Agency, Food and Drug Administration, have published new guidelines for management spinal imaging procedures during the Coronavirus disease (COVID-19) pandemic outbreak Governments in various countries have stressed on the Policy measures, adopted few to Policy measures in the order to slow the disease transmission. The disease transmission rate has decreased the demand for spinal imaging. Governments have asked healthcare provider and manufacturers to facilitate patients with the emergency spinal imaging procedure to save life. The Coronavirus disease (COVID-19) pandemic outbreak is pushing spinal imaging industry boundaries and forcing manufactures and researchers to find new ways of manufacturing new device, equipment’s and accessories with new innovative & unique design, new technologies and new functionality. The DBMR Insights will provides case study based analysis of changes in market dynamics in terms of market share, new entrance, new developments, impact on domestic and localised market players, country level analysis, emerging market, PESTLE analysis, revenue pockets analysis, changes in market regulations, strategic decisions, product approvals, product launches, geographic expansions in the markets. FIGURE 1 DBMR INSIGHTS ON COVID-19 PANDEMIC IMPACT ON GLOBAL SPINAL IMAGING MARKET DYNAMICS understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create an impact solution for COVID-19 pandemic.
Significant Impact of COVID-19 on Global Medical Face Shield Market in Healthcare Industry
COVID-19 Impact on Global Medical Face Shield Market in Healthcare Industry The first case of COVID-19 Pandemic was found in Wuhan, China. This pandemic has influenced the whole planet with its major impacts on the economy and businesses across globe. The COVID-19 spread worldwide in unexpected ways due to its high infectious and contagious nature and lack of availability of its vaccine. As a result, the greatest medical challenge in the 21st century is yet to be faced by physicians worldwide. Though emergence of the virus can be tracked back to Asia, many European countries along with U.S. have been struck massively by the pandemic. The virus has spread across all regions ranging from North America, Europe, Asia-Pacific, Middle East and Africa up to South America. The COVID-19 has been declared as a pandemic by World Health Organization (WHO) as it has created a negative impact on the regions globally. Various countries announced the complete lockdown in the countries such as the U.S., Germany, India and China among more after the declaration of the pandemic in order to decrease its spread. The contagious nature of COVID-19 has increased the demand of medical face shield among people of various professions. According to the situation, the report of 28 July 2020 by WHO stated 16,341,920 cases of corona has been reported globally and 650,805 patients are dead due to the coronavirus. The outbreak of COVID-19 is having a huge impact on the healthcare industry majorly the medical face shield market. IMPACT ON DEMAND The COVID-19 pandemic has lifted the medical face shield industry from its niche pedestal to the mainstream sector. Even before the pandemic, surgical face masks have proved influential in ensuring first-line security against many deadly epidemics in the form of airborne diseases such as Flu, SARS and Zika Virus. The outbreak of COVID-19 pandemic has further expanded the role of medical face shields in various domains. Several companies operating in other domains are eager to enter and some have already entered the landscape of the medical face shield to increase their revenue by meeting the emergent need of protective equipment to stay safe and protected from the virus infection. For instance, · In May 2020, Ripclear, manufacturer of advanced protective films for sports eyewear launched V2 Shield, designed in order to protect personnel battling the COVID-19 outbreak including nurses, police, EMS workers, and other front-line staff. · In May 2020, BAUER Hockey, LLC, a leading manufacturer of hockey equipment’s retooled its manufacturing in order to manufacture medical face shields for healthcare workers and people endangered due to the outbreak of COVID-19 Pandemic. · In April 2020, Mahindra & Mahindra Ltd retooled its Detroit manufacturing facility for producing medical personal protection equipment’s including medical face shields for the localized frontline healthcare workers along with infected masses. · In March 2020, ISAAC BUDMEN INDUSTRIES LLC, a 3D printer manufacturing firm has redirected it 3D printing operations into manufacturing medical face shields in order to meet the increasing demand of PPE due to COVID-19 pandemic. The Center for Disease Control (CDC) and other organizations such as Infectious Diseases Society of America (IDSA) has recommended the use of personal protective equipment (PPE) which includes face shield and face masks. Since the effectiveness of protective equipment increases when both face masks and face shields are worn by the person, therefore they have been adopted in large number by people across globe. Nevertheless, face masks are thought to be more effective in alleviating the spread of respiratory viruses such as SARS-CoV-2, which will serve to eliminate droplets and eye spread. Many scientific studies have showed the high effectiveness of medical face shield in conjugation with the face masks. Therefore the significant rise in the demand of medical face shields could be experienced by the key market players. Medical face shields are made up of various materials such as polycarbonate, propionate and cellulose acetate among more but the demand of polycarbonate based medical face shield is high as compared to others. Moreover, the fear of contamination has also surged the demand of disposable medical face shield as compared to the reusable face shields. Since, the hotspot of COVID-19 pandemic was Asia-Pacific region; the medical face shield market is most rapidly growing in this region. Further rise in the demand of medical face shield is due to the heavy penalties imposed by the government of various regions for the violation of safety regulations of covering their face. This have further escalated the demand and adoption of medical face shields by the workers in industries like chemical, construction, oil & gas, pharmaceutical, and manufacturing to prevent fatal accidents and occupational injuries at the workplace. Such accidents are induced by dangers that occur due to the complexity of the job and the operating climate. In the chemical industry, various chemicals produced can harm workers through direct contact with the skin. Inadvertent absorption and inhalation of gases, vapors and dust can also affect staff. The PPE for the pharmaceutical industry contains face shields to avoid oil splashes and harmful particulate entering directly into the respiratory systems. The enormous benefits and application of medical face shield in various industries along with its capability to provide full face protection and properties like reusability, easy cleaning and no fear of shortage of raw material are anticipated to fuel the growth of medical face shields market. IMPACT ON SUPPLY The COVID-19 situation has led to an overall disrupted supply chains for every market. The sudden outbreak of COVID-19 and its subsequent impact on restrictions on trade and movement of goods has resulted in a shutdown of vast portions of the global economy, resulting in disrupted supply chains due to limited materials and workforce, and slowdown or stopping of manufacturing. However, several companies are retooling for priority manufacturing to produce essential medical supplies and equipment such as ventilators, face masks and medical face shields. The maximum companies which have retooled belong to the business like printing, upholstery and sewing among more. These businesses already used some or the other raw material which is used in order to make medical face shields like acetate sheets in 3D printing, foam in upholstery and elastic ribbon in sewing and other. In this way the supply of the emergent medical face shields have been maintained by various regions. The trade restrictions have left no choice but making domestic manufacturing of essential medical devices a necessity. During the pandemic, as the demand increases, counterfeiting and price gouging of imported goods increase as well. In order to meet the increasing demand of the people across globe various initiatives are being taken by the government, many companies and research institutes. For instance, · In March 2020, the department of mechanical engineering of Massachusetts Institute of Technology (MIT) has launched a new technique for mass manufacturing of medical face shields in order to meet the high demand for disposable face shields by the healthcare professionals during the problematic time of COVID-19 pandemic. KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19 · In June 2020, 3M is streamlining the supply in order to meet the demand of medical face shields in U.S. by shifting their focus and production lines for the development of medical face shields to meet the ever-increasing need of healthcare professionals. · In April 2020, KCWW, a leading manufacturer of clinical solutions for hygiene and more announced to donate USD 8 Million in donations in order to support COVID-19 relief efforts. This donation done by the company during the critical time of COVID-19 pandemic increases its credibility in the market. · In March 2020, Ford Motor Company underwent partnership with 3M and GENERAL ELECTRIC COMPANY in order to develop respirators, ventilators and face shields. This partnership by the companies will aids in meeting the demand of medical face shields by people during the time of COVID-19 pandemic. · In March 2020, Dimensional Innovations with North Kansas City-based InStore Design Display and the University of Kansas' Center for Design Research in order to manufacture medical face shields and meet the demand of supply of medical safety equipment. CONCLUSION The impact of the novel COVID-19 virus is expected to leave a long-lasting impact on each industrial sector. The outbreak of COVID-19 prompted citizens to deal with confusion regarding the virus and its management. The virus poses risk not just with human life but has caused economic distress and severe emotional strain. It produced a ripple effect that gave rise to a new collection of requirements and needs that were not needed earlier. The one of the need being the medical face shields. Earlier the medical face shields were restricted to few medical procedures and industries which involves hazardous chemical use among more. However, the highly contagious nature of virus and its ease of spread via droplets or even fomites to be known to some extent, the demand of medical face shields have escalated in the market. The growing prevalence of these infectious diseases has necessitated the need for a stable healthcare network and adequate emergency medical services (EMS). This has boosted spending in medical services around the globe. The highly contagious nature of the illness has necessitated the need for personal safety devices to discourage healthcare workers from being contaminated with the infection, In fact, staff delivering critical care during the lockout placed in various countries to prevent the transmission of COVID-19, and are forced to wear surgical face masks along with face shields in order to secure them. These factors are fueling the growth of medical face shield market. Although, development in the medical face shield market would be highly reliant on therapeutic approaches to tackle COVID-19, even after the vaccine has become effective, the strategy is likely to remain preventive. In general, customizable face shields may become a possibility, particularly when children go back to school. Once vaccinations are accessible on a wide scale, the usage of face shields and face masks may stay strong. Nevertheless, the long-term market outlook remains steady, because citizens are likely to take a preventive approach. Despite the indication of a drug or vaccination on the horizon, the pandemic is here to live for a considerable amount of time. As a consequence, wearing surgical masks and face shields would become a common trend thereby increasing the development and growth of medical face shields market.
Significant Impact of COVID-19 on Favipiravir in Pharmaceutical Industry
COVID-19 Impact on Favipiravir in Pharmaceutical Industry OVERVIEW A novel corona virus, SARS-CoV-2, appeared in December 2019 in Wuhan, China, spreading much faster than its predecessors and the virus has already infected millions of patients worldwide as of April 19, 2020. As the scope of the current COVID-19 outbreak has reached proportion of pandemics, major international efforts in public health are underway to control the outbreak. However, as definitive treatments for confirmed COVID-19 are yet to be identified, there is considerable interest in repeating existing antiviral drugs for use against COVID-19. Favipiravir triphosphate is a purine nucleoside analogue. This acts as a competitive inhibitor of RNA-dependent RNA polymerase. It has activities against influenza A and B, including oseltamivir- and zanamivir-resistant influenza viruses, several antimicrobial antiviral drugs, such as SARS-CoV-2. Favipiravir is approved for influenza strains that do not respond to standard antiviral therapy in Japan. IMPACT ON PRICE A large number of challenges are being faced by various market players due to the coming of the novel coronavirus, one such issue is the uncertainty surrounding the impact of covid-19 on favipiravir demands. Due to the increased demand of favipiravir for coronavirus treatment and stiff competition between the market players the rice of favipiravir has decreased. According to the data available even as physicians share the benefits of Favipiravir for mild to moderate COVID-19 patients, a number of general launches are anticipated to intensify the price war that has already begun., Last month, Glenmark Pharma has receive a regulatory approval for Favipravir which has lowered its tablet price to Rs 75 each from Rs 103 earlier, anticipating market competition. 8 other favipiravir brands are at least expected to be launched in the upcoming days. At a price of Rs 59 per tablet, the Hetero Pharma became the third company to launch its generic version of Favipiravir, called Favivir. Previously, Mumbai-based Jenburkt Pharma put the low cost brand to date, Favivent, at Rs 39 per tablet. The company has started stockpiling in Mumbai and aims to expand its share of Maharashtra before it expires nationwide. With the increasing demand and increasing sale of favipiravir drugs, the competition between the favipiravir drugs manufacturers has increased market, leads to the fall of favipiravir drugs price. IMPACT ON DEMAND The Corona virus zone is the result of various markets around the world. This is the cause of the widespread closures and isolation that are affecting world economic activity. In Japan Favipiravir which is an oral antiviral drug approved for the treatment of influenza. It specifically inhibits RNA polymer, which is necessary to copy the virus. Japan has begun a Phase 3 clinical trial. In the United States, a phase 2 study will involve approximately 50 patients with COVID-19, in collaboration with Brigham and the Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School. In India, a Phase 3 trial began combining two antiviral drugs, favipiravir and umifenovir, in May 2020. Chemists and pharmacists are in the high demand for the antiviral drug Favipiravir, which was launched under the brand name "fabi-influenza" by Glenmark drugs. It has been approved for limited emergency use in for the COVID-19 patients with mild to moderate symptoms by (ICMR) Indian Council of Medical Research. The impact of COVID-19 has created an opportunity for the number of patients as there are high chances of adverse health effects of COVID-19 on the people. IMPACT ON SUPPLY As the epidemic intensifies, supply chains can be at significant risk due to over-located locations that can potentially be disrupted. The supply chain of drugs has been disrupted. The spread of COVID-19 makes it difficult for governments to use these drugs; the availability of these systems faces constant challenges due to their components of use as well as limited initial needs. Lasa Supergenerics already has export orders from abroad. The drug is sought after in Turkey, Jordan, Spain, and Portugal and so on where it is used in COVID-19 patients. Exports have no restrictions as they are based on our own specifications and not under the name of specific pharmacology. This is an opportunity to confirm that India is indeed the 'Pharmacology of the World'. As the world seems to be using reusable drugs to control COVID-19 until an effective and safe vaccine is developed, India has played a key role in providing some key drugs such as hydroxychloroquine (HCQ) and favipiravir for humanitarian and commercial purposes. The trade restrictions have chosen nothing more than to produce the necessary medicines domestically. During the pandemic, when the demand increases, counterfeiting and price increases of imported goods increase. This signifies that even during the COVID-19 pandemic the market players are able to maintain supply chain. STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS As the coronavirus continues to spread to various countries, concerns are growing about disruptions in drug production and distribution. Collaborations, agreements, initiatives of market participants such as Fujifilm Corporation in the pharmaceutical market have helped them to expand their market. This in turn will help to increase the demand for the product among the consumers and thus increase the future sales of the company. Market players have already taken different initiatives to combat the corona virus. For instance, · In July 2020, Hyderabad's Hetero group announced that the generic drug Favipiravir would be introduced in India under the brand name "Favilavir" for the treatment of mild to moderate COVID-19. Hetero obtained approval from the Indian Anti-Doping Agency (DCGI) to manufacture and market the generic drug. · In July 2020, Cipla Limited announced that it has received the approval of the Indian anti-doping agency (DCGI) to place favipiravir in the country under the Ciplenza brand. Early approval for the manufacture and marketing of the drug aims to meet the urgent and undeveloped medical need for COVID-19 treatment options in the country with limited emergency use. It has been developed jointly by Cipla and the CSIR (Council of Scientific and Industrial Research) - Indian Institute of Chemical Technology (IICT). As part of this partnership, CSIR-IICT has successfully developed a convenient and cost-effective process for Favipiravir. The whole process and the active ingredient (API) of the medicine have been transferred to Cipla to manufacture and market the medicine in magnitude. · In July 2020, The Indian pharmaceutical company giant Dr. Reddy's Laboratories (Dr Reddy's) has signed a tripartite agreement with Fujifilm Toyama Chemical and Dubai Response Global Aid (Dubai) for the development, production and sale of the favipiravir innovation brand Avigan. Under the terms of the agreement, it is assumed that FUJIFILM will receive a license fee and commissions for sales from Dr. Reddy and GRA. Dr Reddy has exclusive rights to manufacture Avigan, while both GRA and Dr Reddy have joint the rights to develop, sell the market the drug worldwide except Japan, China and Russia. · In June 2017, In India, Glenmark Pharmaceuticals has started in Phase III clinical trials of the drug. The results of the Glenmark study, which records up to 150 patients, will be available in July or August 2020. · In April 2017, Fujifilm Corporation (Tokyo, Japan) has initiated a clinical trial in II. Stage study to evaluate the safety and efficacy of the influenza antiviral drug Avigan tablet (synonymous with favipiravir) in patients with COVID-19, a respiratory tract infection caused by the novel SARS-CoV-2 coronary heart virus. Avigan was the first antiviral drug approved for use in the treatment of COVID-19 in China. At the beginning of March, when production in Avigan began, the company was producing approximately 40,000 treatment courses per month. The company plans to gradually increase this to up to 100,000 treatment courses per month by the end of July (approximately 2.5 times more). The overall goal, according to FUJIFILM, is to accelerate the production of up to 300,000 treatment courses per month by September 2020. With the increasing demand and increasing sale of favipiravir drugs, are fueling the growth of favipiravir drugs market in the near future. As such, market participants are involved in the production of favipiravir drugs expanding their business through a variety of programs, including collaboration, contracts, and pipeline development, collaboration, and market expansion. It is expected that the strategic decisions of these companies will provide significant opportunities for market participants operating in the favipiravir market. CONCLUSION The available clinical evidence suggests that favipiravir is relatively safe for total cell carcinoma, as well as serious gastrointestinal side effects. However, an increase in the blood uric acid is still a safety issue, as shown in a pooled analysis of larger studies, with evidence of increased dose-dependent development. Further safety concerns, such as the possibility of Corrected QT Interval (QTc) malformation and prolongation, have not yet been adequately investigated. There is an evidence to support the safety and tolerability of favipiravir during short-term treatment. However, more evidence is needed to assess the effects of long-term treatment. Given the limitations of the evidence and the specific safety concerns that remain, the widespread use of favipiravir against pandemic COVID-19 should be justified. Various manufacturers have allowed their manufacturers to remotely operate the production of favipiravir at various production sites in safe areas around the world and help them maintain a stable supply chain. In addition, increased demand for favipiravir for the treatment of coronavirus has increased profits.
Impact of COVID-19 on Medical Cannabis in Healthcare Industry
COVID-19 Impact on Medical Cannabis in Healthcare Industry OVERVIEW The COVID-19 has posed a complex challenge in front of different companies that are using medical cannabis to produce health care products, which has badly impacted the worldwide market. However, it has boosted the growth of companies involved in vaccine development and moreover various studies are being conducted so as to use the medical cannabis in the treatment of COVID-19 due to its anti-inflammatory properties, as there is great need of vaccine which can act against Coronavirus and prevent this deadly disease so various major players of the markets are coming forward so that a novel vaccine can be produced as early as possible. PRICE IMPACT The COVID-19 has resulted in a number of countries imposing restrictions on several aspects of healthcare that have impacted several markets and their economies. The overall revenues for the market are somehow less affected even in these pandemic situations because of its medical benefits. The market is propelling because of its benefits in the chronic diseases. Many experts suggest that medical cannabis can aid with the treatment of COVID-19, as previous study has shown that a variety of pro-inflammatory cytokines, including IL-6, can be decreased by CBD, which is reduced by several other medications being investigated for the treatment of COVID-19. And the CBD is undergoing numerous studies so that a perfect vaccine can be made. The price is not impacted significantly as several entities are using the medical cannabis in a large amount due to its various advantages in treatment of various diseases. But in some places the price is increasing a little bit due to the dry supply in the areas where the medical cannabis is imported. IMPACT ON DEMAND Despite the COVID-19 pandemic, the medical cannabis demand is still increasing some areas. Like the European medical cannabis demand is strong and continuously growing at a very good speed. But due to COVID-19 pandemic the legislation efforts in various countries is hampered, which is somehow the main reason for delay in demand drives the consumers towards the unregulated market. Mainly the demand for medical cannabis is increasing from the European countries and the markets mainly serves around 5.9% of total population of 28 European countries. Medical cannabis have shown a lot of changes in the treatment of a diseases due to its anti- inflammatory properties, that’s why many countries are trying to legalize the production and usage of medical cannabis but only in healthcare market. Also a similar growth is seen in the U.S. market as consumers have stocked up the medical cannabis. Since medical cannabis is consumed alone, the majority of consumers are opting to consume the medical cannabis by themselves. Now there are various innovation and evolution in the production of medical cannabis so that the drug doesn’t cause any side effects and can be produced in the form of edibles or infused products. IMPACT ON SUPPLY CHAIN Due to pertinacious COVID-19 lockdown, sanctions have been imposed by governments of various countries. These restrictions and barriers across countries borders led to a decrease in supply of medical cannabis across borders. The COVID-19 outbreak has disrupted the supply chains for medical cannabis, and in coming few months it will be challenging to maintain the supply chain. Health services, including the time and attention of healthcare practitioners, are in limited supply and are geared towards handling the spread of the disease. Some regions or areas that were totally depended on the imports from other regions will face various challenges in coming time due to restrictions in border and even the staff will be unavailable. The trade restrictions have impacted the market inversely. Since the demand is increasing for the medical cannabis in the healthcare market the government will try to improve the growth of supply chain, and also will take various decisions so that the medical cannabis is used for betterment of individuals only. STRATEGIC DECISIONS FOR MANUFACTURERS The leading players are collaborating, expanding their business in various regions and even taking more crucial steps in advancement of R&D. For instance, · Cresco labs have expanded its business in the Ohio market by acquiring four dispensaries. Several research institutes and medical cannabis producers are working together in the coming months to create a novel vaccine for the treatment and prevention of COVID-19 disease. The manufactures are also paying a lot of attention in the development of innovative products that can be used for the desirable effects. Also the manufactures are more focused on the production of medical cannabis products that are related to health care only, so that the demand from hospitals and various researches intitule can be increased in this pandemic. Companies operating in the market are adopting several strategies, including collaboration, agreements, partnership, and market expansion to enhance their business. These strategic decisions by the companies are expected to provide significant opportunities for the market players operating in the vaccine market. The coming months can be considered challenging for manufacturers. Supply chain managers might want to consider dealing with OEMs that are able to overcome market disruptions. Manufacturers need to take necessary steps pertaining decisions regarding production processes, shifting to other facilities if needed, changes in quality assurance, costs and processes related to screening of workforce and offering of care if required, changes in working hours, and others. CONCLUSION The demand for medical cannabis is expected to rise in coming few months due to legalization in various growing markets. However, the demand will stay unaltered due to the benefits of medical cannabis during the COVID-19 pandemic. The existing market leaders holding major share in the market that are cash rich and have strong strategic teams will be least impacted.. However, as the situation eases, the sales will bounce back. Taking strategic steps will help the companies to exhibit planning and demonstrate stability to the end users. Moreover the legalization of medical cannabis in the healthcare market will be a boom for various manufactures, as the demand will increase and so as the supply chain will be improved.
Thảo dược An Quốc Thái
Đội ngũ nhân viên, ban cố vấn y tế, sức khỏe có chuyên môn cao Thảo dược An Quốc Thái có một đội ngũ nhân viên tư vấn rất nhiệt tình, luôn luôn sẵn sàng với bất kỳ thắc mắc, câu hỏi nào của khách hàng về các vị thuốc, các bệnh tật, chăm sóc sức khỏe như thế nào cho tốt,… Không có tình trạng ép mua thuốc, hay tư vấn sai, bởi chúng tôi luôn đặt tiêu chí sức khỏe khách hàng nên hàng đầu. Đội ngũ chuyên gia đồng hành cùng chúng tôi, chia sẻ những kinh nghiệm chữa bệnh, những công dụng của các loại thảo dược: Dược sĩ Lý Kiến Bình – Giám đốc Thảo dược An Quốc Thái. Dược sĩ bác sĩ Phan Thị Sa: Đã từng học: Trường Đại học Y dược TP Hồ Chí Minh. Hiện tại phụ trách nội dung viết bài trên https://caythuoc.vn của thảo dược An Quốc Thái. Facebook: https://www.facebook.com/people/B%C3%A9-Sa/100041836666799 Twitter: https://twitter.com/BDng22969917 Linkedin: https://www.linkedin.com/in/sa-phan-b699b5196/ Lương y bác sĩ: Phạm Thái An - Cố vấn chuyên môn của Thảo dược An Quốc Thái. Pinterest: https://www.pinterest.com/anquocthai/ Fanpage của thảo dược An Quốc Thái: https://www.facebook.com/caythuocthiennhienvietnam Thông tin liên hệ: Thảo dược An Quốc Thái Website: https://caythuoc.vn Địa chỉ: 62/1/28 Trương Công Định, P.14, Q.Tân Bình, TP. HCM Hotline: 0926456456 (Viettel)
Where Can I Buy Xanax Tablets Without a Prescription
Nowadays in this pandemic situation of Covid-19, everyone is stressed and worried about their health. Their unhealthy and hectic lifestyles are the root cause behind several health diseases such as Anxiety, Depression, Insomnia, and sleeping disorder problems. If you want to buy xanax, then you can buy xanax online without prescription only with a single click at Diazepamshoponline  These health diseases are getting common nowadays. Because, around 7 out of 10 people are suffering from all these kinds of health problems. Especially, in the UK, USA, and other big country; these problems are getting worse day by day. The busy working lifestyles, over thinking, improperness in sleep can easily lead all of these health issues. If these anxiety, depression, insomnia, and sleeping disorder problems happen for a short period of time then it is completely normal. But if it is getting happen on a regular basis or you are not able to get rid of these problems by yourself easily, we recommend you to kindly get in touch with your nearest doctors or pharmacists. Why Xanax tablet is highly recommended? To overcome Anxiety, depression, insomnia, and sleeping disorder problems; top doctors and pharmacists of the UK and the USA recommend Xanax tablet. Because, Xanax tablet contains sedative properties with low-risk potential and also it is very useful for the patients who are having problems of Muscle spasms and seizures. Xanax tablet has high tolerability multimodal functional phenomena that make it a more reliable drug to efficiently treat Anxiety problems. The doctors suggest Xanax tablet as an ideal set drug to cure all of these problems related to anxiety disorder and sleeping disorder problems very effectively. People can use Xanax tablet and get rid of their problems. More about Xanax: Xanax tablet is a highly prescriptive set of drug because it is the part of benzodiazepine group of drug and Alprazolam is the brand that produces Xanax tablet. Xanax tablet is the cheapest anti-anxiety sleeping capsule you can ever purchase in the UK and the USA. Although, it is a prescriptive drug, the patient should follow the prescriptions and precautions precisely to avoid any kind of negative side-impacts of this drug.  You cannot use Xanax tablet if you don’t have a proper set prescription. You can find many other sleeping pills in the market but Xanax are the most reliable and trusted anti-anxiety drug by the users and doctors. It is the best-anti-dote to cover all of these problems very easily and also it helps you to reduce and manage the anxiety levels f the patients. But still, you should discuss the risks and benefits of using Xanax tablets with your doctor.     To know more and buy Xanax tablet online in the UK, follow this link: – www.diazepamshoponline.com How does it affect the human-body? : The sedative properties of Xanax tablet produce a calming effect to the brain that helps to normalize and manage the anxiety level in the body. The patients can feel those ease in their body after using this drug precisely. Their body starts gradually reducing the sign of Anxiety, depression, and stress. The patients can easily able to get a proper nap of sleep and by precise use of Xanax tablets. To make yourself relax, comfortable, and free from all of these diseases, use Xanax tablets. Purchase your Xanax tablets now. Click on this link to purchase Xanax tablet easily- http://diazepamshoponline.com/shop Why should you choose our online pharmacy to shop Xanax tablet online in the UK? If you want to purchase Xanax tablet in the UK, you can either choose a local medical shop or a online drug store. The local medical shopkeeper will ask you for a prescription that might be bother you sometimes in case if you don’t have any prescription. At that time you cannot purchase Xanax tablet. Therefore, to get rid of this issue, the online availability of Xanax tablets are accessible in the pharmacy market of the UK.   Hence, Xanax online UK helps you to feel at ease: Yes, nowadays; the online accessibility of Xanax tablets is possible. People can purchase Xanax tablets online and can grab much more benefits such as- You don’t need to worry about any kind of prescription; you can easily purchase Xanax tablets without prescription.  Also, you can get the cheapest anti-anxiety sleeping tablet (Xanax Tablet) online in the UK. Note: Buy Xanax tablets online today from our online pharmacy and treat your anxiety problems efficiently with maximum discounts. Best place to purchase Xanax tablets online in the UK without prescription: – www.diazepmshoponline.com Does Xanax tablet have some side-effect? Since, Xanax tablet is a prescriptive drug and random allowance of this drug is not accessible. Therefore, use this drug under the proper guidance of doctors or pharmacists. Improper use of Xanax tablets can lead several side-effects such as- Fatigue Weakness Sight blur Irritated Confusion Lack of body coordination and unsteadiness Drowsiness and Dizziness Headache and body pain Restlessness To avoid all of these negative impacts, Use Xanax tablets, follow the precautions and prescriptions precisely while using Xanax tablets.